HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fine, S. R. Articles by Ginsberg, P. Search for Related Content PubMed PubMed Citation Articles by Fine, S. R. Articles by Ginsberg, P.

From Christ Hospital in Jersey City (Dr Fine) and the Division of Urology at the Albert Einstein Medical Center in Philadelphia (Dr Ginsberg).

Address correspondence to Shari R. Fine, DO, University of Medicine and Dentistry of the New Jersey School of Osteopathic Medicine, Department of Family Medicine, 324 Palisade Avenue, Jersey City, NJ 07307.E-mail: sfine324{at}verizon.net

Benign prostatic hyperplasia (BPH) is highly prevalent in men older than 50 years and is associated with a range of lower urinary tract symptoms that may have a negative impact on patient quality of life. Alpha₁-adrenergic receptor antagonists are the first-line of pharmacologic management for lower urinary tract symptoms associated with BPH. However, many patients take multiple medications that may exacerbate age-related orthostatic hypotension. Thus, clinicians should evaluate the treatment of these patients within the context of comorbidities. The present article discusses the role of non–subtype-selective and subtype-selective ₁-adrenergic receptor antagonists in the clinical management of BPH. Safety and tolerability for both non–subtype-selective and subtype-selective ₁-adrenergic receptor antagonists for patients with BPH are also reviewed.